Dec. 18 at 4:26 PM
$MED down 14.1% in 6 months — is it time to pivot to growth? 📉
Medifast is focusing on metabolic health and digital tools to address evolving weight-loss dynamics, yet it carries a Zacks Rank #4 (Sell). Meanwhile,
$COCO boasts Zacks Rank #1, with impressive growth and earnings surprises, and
$MNST sports a Zacks Rank #1.
Opportunity assessment here 👉 https://www.zacks.com/stock/news/2806338/can-medifast-overcome-glp-1-pressure-with-its-growth-strategy?cid=sm-stocktwits-2-2806338-body-25453&ADID=SYND_STOCKTWITS_TWEET_2_2806338_BODY_25453